INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Frankfurt
11.11.26 | 09:55
1,270 Euro
+9,48 % +0,110
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,270 | 1,480 | 10:19 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:06 | Innate Pharma SA: Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026 | 268 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that it will host an event focused on IPH4502, its proprietary Nectin-4 ADC. The... ► Artikel lesen | |
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| Di | Innate Pharma auf der Stifel Healthcare Conference: Onkologie-Pipeline steuert auf entscheidende Wendepunkte zu | 2 | Investing.com Deutsch | ||
| Do | Innate Pharma stock maintained at Buy by BTIG on pipeline progress | 1 | Investing.com | ||
| Do | Innate Pharma reports €96.8M in cash, outlines key 2027 pipeline milestones | 1 | Seeking Alpha | ||
| Do | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Do | Innate Pharma SA: Innate Pharma Reports Third Quarter 2026 Business and Financial Update | 307 | Business Wire | Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event Lacutamab, partnered with Sobi, progressing toward... ► Artikel lesen | |
| 27.10. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.10. | Innate Pharma SA: Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 | 337 | Business Wire | PACIFIC-9 Phase 3 trial led by AstraZeneca evaluates durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC
Regulatory News:
Innate Pharma SA (Euronext Paris:... ► Artikel lesen | |
| 21.10. | Innate Pharma SA: Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference | 354 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 20.10. | Innate Pharma SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 20.10. | Innate Pharma SA: Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update | 384 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announces that the Company will hold a conference call on Thursday, November 5, 2026, at... ► Artikel lesen | |
| 21.09. | Innate Pharma stock maintained at Buy by H.C. Wainwright | 2 | Investing.com | ||
| 18.09. | Innate Pharma Extends Cash Runway Through Q1 2028 As Sobi Partnership Advances Lacutamab Into Phase 3 | 1 | pulse2.com | ||
| 17.09. | Innate Pharma SA H1 Loss Drops | 1 | RTTNews | ||
| 17.09. | Innate Pharma übertrifft Q2-Prognosen, doch die Aktie gibt nach | - | Investing.com Deutsch | ||
| 17.09. | Innate Pharma H1 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 17.09. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.09. | Innate Pharma gives H1 results | 3 | Seeking Alpha | ||
| 17.09. | Innate Pharma SA: Innate Pharma Reports First Half 2026 Business Update and Financial Results | 802 | Business Wire | New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027 €30 million equity financing... ► Artikel lesen | |
| 16.09. | Innate Pharma closes Sobi partnership, receives $75m upfront | 2 | Investing.com |
1 2 3 4 Weiter >>
67 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVORYON THERAPEUTICS | 0,728 | +2,82 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| TME PHARMA | 0,103 | -1,53 % | TME Pharma NV: TME Pharma provides further details on the exclusive negotiation agreement with TMS Co., Ltd. for NOX-A12 | ||
| CANSINO BIOLOGICS | 3,000 | -1,32 % | CanSino Biologics Inc: CanSinoBIO Reports Growth in First Nine Months: Commercialization Accelerates Across Multiple Products as Platform Innovation Opens New Avenues for Growth | HONG KONG, Oct 27, 2026 - (ACN Newswire) - On October 27, 2026, CanSino Biologics Inc. (HKEX: 06185; SSE: 688185) released its third-quarter financial report for 2026. For the nine months ended September... ► Artikel lesen | |
| ADICET BIO | 2,700 | +0,75 % | Adicet Bio GAAP EPS of -$1.76 misses by $0.17 | ||
| KARYOPHARM | 0,024 | 0,00 % | XFRA 25K0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKARYOPHARM TH.NEW.DL-0001... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,260 | -3,70 % | Mereo BioPharma Group GAAP EPS of -$0.01 in-line, revenue of $0.80M | ||
| ANNOVIS BIO | 0,788 | +1,42 % | Annovis chairman invests $5M in $21M public offering | ||
| INTEGRA LIFESCIENCES | 13,000 | +3,17 % | Integra LifeSciences auf UBS-Gesundheitskonferenz: Erholungskurs gewinnt an Kontur | ||
| RHYTHM PHARMACEUTICALS | 102,00 | -0,97 % | Rhythm Pharmaceuticals-Aktie: Übernahmegerüchte, wilder Kursverlauf! | Der britische Pharmakonzern AstraZeneca soll ein Übernahmeangebot von rund zehn Milliarden US-Dollar für das US-Biotechunternehmen Rhythm Pharmaceuticals unterbreitet haben. Branchenberichte und neue... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 2,720 | 0,00 % | Neuphoria Therapeutics, Inc.: Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc | Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria"... ► Artikel lesen | |
| RECCE PHARMACEUTICALS | 0,188 | +3,87 % | RECCE PHARMACEUTICALS LTD: Final Director's Interest Notice - Mr McKeough | ||
| MABION | 1,672 | -0,24 % | ODDIFACT: Oddifact and Mabion Receive FDA Pre-IND Meeting Grant for RTX-NP (MabionCD20) in Immune Thrombocytopenia | FDA grants Type B pre-IND meeting, enabling critical alignment with the Agency on the development strategy for RTX-NPOddifact and Mabion aim to bring rituximab's well-established activity in ITP... ► Artikel lesen | |
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase |
Das Unternehmen INNATE PHARMA SA ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,270 Euro und damit +9,48 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.